CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 4.12 USD 3% Market Closed
Market Cap: 698.1m USD

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 7.21 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
47% Upside
Average
Price Target
7.21 USD
75% Upside
Highest
Price Target
10.5 USD
155% Upside
CytomX Therapeutics Inc Competitors:
Price Targets
688331
RemeGen Co Ltd
17% Upside
CUV
Clinuvel Pharmaceuticals Ltd
100% Upside
CYTK
Cytokinetics Inc
27% Upside
300896
Imeik Technology Development Co Ltd
40% Upside
PHARM
Pharming Group NV
43% Upside
ATX
Amplia Therapeutics Ltd
257% Upside
LXRX
Lexicon Pharmaceuticals Inc
141% Upside
RXRX
Recursion Pharmaceuticals Inc
63% Upside

Revenue
Forecast

Revenue Estimate
CytomX Therapeutics Inc

For the last 10 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 39%. The projected CAGR for the next 4 years is -22%.

39%
Past Growth
-22%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-79%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
7.21 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 7.21 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-22%

For the last 10 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 39%. The projected CAGR for the next 4 years is -22%.

Back to Top